image credit: Unsplash

Impressive Disease Control in Metastatic Triple-Negative Breast Cancer

May 14, 2021

An investigational antibody-drug conjugate (ADC) achieved disease control in all but one patient with advanced or metastatic triple-negative breast cancer, results of a preliminary clinical study showed.

Nine of 21 evaluable patients had objective responses and 11 had stable disease when treated with datopotamab deruxtecan (Dato-DXd). The study population had a median treatment history of four prior systemic regimens, and 21 of 24 patients enrolled in the trial had received at least two prior regimens.

Read More on MedPageToday